Olgu Sunumu
BibTex RIS Kaynak Göster

Miyelom Zimba Gibi Gelir: Roy Adaptasyon Modeli Bir Olgu Sunumu

Yıl 2023, , 263 - 271, 08.09.2023
https://doi.org/10.32708/uutfd.1273377

Öz

Multiple miyelomlu bireylerde semptom yönetimi, kemik hastalığı ve böbrek fonksiyon bozukluğuna bağlı semptomlar başta olmak üzere, enfeksiyon, anemi, ağrı ve pıhtılaşma bozukluğu gibi spesifik sorunları içermektedir. Diğer hastalıklarda olduğu gibi, miyelomlu hastanın tanı ve tedavi sürecinde hemşirelik bakımı önemli bir yer tutmaktadır. Hemşirelik bakım modelleri hastanın sistematik ve kapsamlı şekilde ele alınmasını sağlayarak bakımının kalitesinin arttırılmasına katkıda bulunmaktadır. Roy Adaptasyon Modeli bunlardan biridir. Roy Adaptasyon modelinde fizyolojik, benlik kavramı, rol fonksiyonu ve karşılıklı bağlılık olmak üzere dört uyum alanı vardır ve hemşireler hastalarına bu uyum alanları doğrultusunda bakım vermektedir. Olgu sunumunda, bel ağrısı nedeniyle başvuran radyolojik, laboratuvar, sitogenetik ve kliniği ile Durie Salmon’a göre lambda hafif zincir, evre III B multiple miyeloma tanısı almış ve ayaktan kemoterapi tedavi planı hazırlanmış bir hasta ele alınmaktadır. Bu olgu sunumu, Multiple miyelomlu bir hastaya Roy Adaptasyon Modeli doğrultusunda verilen bakımın North American Nursing Diagnosis Association hemşirelik tanılarıyla birlikte ele alınması konusunda, hematoloji ve onkoloji alanında çalışan hemşirelere rehber olmak amacıyla hazırlanmıştır.

Teşekkür

Bu olgu sunumunu yazmamıza izin veren hastaya, tanı, tedavi ve bakımını yöneten sağlık profesyonellerine teşekkür ederiz.

Kaynakça

  • 1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020 : GLOBOCAN estimates of ıncidence and mortality worldwide for 36 cancers in 185 countries. 2021;0(0):1-41. doi:10.3322/caac.21660
  • 2. Public Health Institution. 2013 - 2018 National Cancer Control Plan, T.C. Ministry of Health. Page 0-94.
  • 3. Konstantinidis TI, Spinthouri M, Ramoutsaki A, Marnelou A, Kritsotakis G, Govina O. Assessment of unmet supportive care needs in haematological cancer survivors. Asian Pacific J Cancer Prev. 2019;20(5):1487-1495. doi:10.31557/APJCP.2019.20.5.1487
  • 4. Boland EG, Boland JW, Ezaydi Y, Greenfield DM, Ahmedzai SH, Snowden JA. Holistic needs assessment in advanced, intensively treated multiple myeloma patients. Support Care Cancer. 2014;22(10):2615-2620. doi:10.1007/s00520-014-2231-2
  • 5. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086-1107. doi:10.1002/ajh.26590
  • 6. World Health Organisation. Global multiple myeloma statistics. International Agency for Research on Cancer. Published 2020. Accessed February 23, 2022. https://gco.iarc.fr/today/data/factsheets/cancers/35-Multiple-myeloma-fact-sheet.pdf
  • 7. Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(94):1-10. doi:10.1038/s41408-020-00359-2
  • 8. Kleber M, Ntanasis-Stathopoulos I, Terpos E. BCMA in multiple myeloma a promising key to therapy. J Clin Med. 2021;10(18):1-17. doi:10.3390/jcm10184088
  • 9. Aghaee M, Ledzewicz U, Robbins M, Bezman N, Jay H, Moore H. European Journal of Pharmaceutical Sciences Determining optimal combination regimens for patients with multiple myeloma. Eur J Pharm Sci. 2023;187(June):106492. doi:10.1016/j.ejps.2023.106492
  • 10. Gallaher J, Larripa K, Renardy M, et al. Methods for determining key components in a mathematical model for tumor–immune dynamics in multiple myeloma. J Theor Biol. 2018;438(7):31-46.
  • 11.Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label,randomized trial. J Clin Oncol. 2011;29(8):986-993. doi:10.1200/JCO.2010.31.6844
  • 12.NCCN. NCCN Guidelines Version 4.2022 Multiple Myeloma.NCCN Clinical Practice Guidelines in Oncology (NCCNGuidelines® ). Published 2021. www.nccn.org/patients
  • 13.Zeng L, Huang H, Liu Y, et al. The core symptom in multiplemyeloma patients undergoing chemotherapy: a networkanalysis. Support Care Cancer. 2023;31(5):297. doi:10.1007/s00520-023-07759-7
  • 14.Nielsen LK, Larsen RF, Jarlbaek L, Möller S, Jespersen E. Health-related quality of life in patients with multiple myelomaparticipating in a multidisciplinary rehabilitation program. Ann Hematol. 2021;100(9):2311-2323. doi:10.1007/s00277-020-04356-0
  • 15.Ovayolu O, Ovayolu N, Aytac S, Serçe S, Sevinc A. Pain in cancer patients: pain assessment by patients and family caregivers and problems experienced by caregivers. Support Care Cancer. 2015;23(7):1857-1864. doi:10.1007/s00520-014-2540-5
  • 16.Bertolotti P, Colson K, Bilotti E, Curran K, Doss D, Faiman B.Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the International Myeloma Foundation’s Nurse Leadership Board. Clin J Oncol Nurs. 2008;12(30):9-12. doi:10.1188/08.CJON.S1.9-12.
  • 17.Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548. doi:10.1016/S1470-2045(14)70442-5
  • 18.Jones & Bartlett Learning L. The Roy Adaption Model: SisterCallista Roy. In: Nursing Theories: A Framework for Professional Practice. Jones-Bartlett Learning, LLC; 1991:127-142. http://samples.jbpub.com/9781449626013/72376_ch10_masters.pdf
  • 19.Maryati I, S S, Mamuroh L. the Application of “Roy Adaptation” theory model in women with early stage ofcervical cancer: a study case. J Matern Care Reprod Heal. 2018;1(2):386-397. doi:10.36780/jmcrh.v1i2.47
  • 20.Jennings KM. The Roy adaptation model: A theoretical framework for nurses providing care to individuals with anorexia nervosa. Adv Nurs Sci. 2017;40(4):370-383. doi:10.1097/ANS.0000000000000175
  • 21.Ursavaş FE, Karayurt Ö, İşeri Ö. Nursing approach based onRoy Adaptation Model in a patient undergoing breast conserving surgery for breast cancer. J Breast Heal. 2014;10:134-140.
  • 22.Akyol E, İbrahimoğlu Ö. Kalp Nakli Olan Hastanın Roy Adaptasyon Modeli’ne göre hemşirelik bakımı. J Cardiovasc Nurs. 2020;11(26):140-148. doi:10.5543/khd.2020.21043
  • 23.Roy C. Extending the roy adaptation model to meet changing global needs. Nurs Sci Q. 2011;24(4):345-351. doi:10.1177/0894318411419210
  • 24.Ramini SK, Brown R, Buckner EB. Embracing changes: adaptation by adolescents with cancer. Pediatr Nurs. 2008;34(1):72-79.
  • 25.Hannon-Engel SL. Knowledge Development: The RoyAdaptation Model and Bulimia nervosa. Nurs Sci Q. 2008;21(2):126-132. doi:10.1177/0894318408315015
  • 26.Yıldız E, Karagözoğlu Ş. Lenfoma tanısı alan yetişkin bireyin roy adaptasyon modeline göre hemşirelik bakımı. J Heal Sci. 2015;90(312):0-2.
  • 27.Menekli T, Çil Eyi S. Use of Roy Adaptation model in nursingcare of a case obesity. Florence Nightingale Hemşirelik Derg. 2017;25(3):237-246. doi:10.17672/fnjn.343263
  • 28.Baksi Şimşek A, Dicle A. Nursing model and care: evaluation with the Roy Adaptation Model of patients with primary brain tumor. Hemşirelikte Eğitim ve Araştırma Derg. 2015;12(3):224-232. doi:10.5222/head.2015.224
  • 29.Özkaraman A, Özer S, Balcı Alpaslan G. Romatoid artritli bir vakanın hemşirelik bakımında Roy Adaptasyon Modelininkullanımı. Gümüşhane Üniversitesi Sağlık Bilim Derg. 2012;1(3):138-152.https://dergipark.org.tr/tr/pub/gumussagbil/98959
  • 30.Wilkinson JM, Barcus L. Pearson Hemş􀧻rel􀧻k Tanıları El K􀧻tabı : NANDA-I Tanılar, NIC G􀧻r􀧻ş􀧻mler􀧻, NOC Çıktıları. 11th ed. (Kapucu S, Akyar I, Korkmaz F, eds.). Pelikan Yayınevi; 2018.
  • 31.Fawcett J. Contemporary nursing knowledge analysis and evoulation of nursing models and theories. 2th ed. Philadelphia: Fa Davis Company; 2005.
  • 32.Longacre ML, Weber-Raley L, Kent EE. Cancer caregiving while employed: caregiving roles, employment adjustments, employer assistance, and preferences for support. https://doi.org/10.1007/s13187-019-01674-4. J Cancer Educ. Published online 2019. doi:10.1007/s13187-019-01674-4
  • 33.Kiyancicek Z, Caydam DO. Spırıtual needs and practıces among famıly caregıvers of patıents wıth cancer. Acta Paul Enferm. 2017;30(6):628-634.
  • 34.Huang MF, Huang WH, Su YC, et al. Coping Strategy and Caregiver Burden among Caregivers of Patients with Dementia. Am J Alzheimers Dis Other Demen. 2015;30(7):694-698. doi:10.1177/1533317513494446
  • 35.Ovayolu Ö, Ovayolu N. Multipl miyelom tanısı alan geriatrik hastalarda ağrı ve yönetimi pain and ıts management in geriatric patients diagnosed with multiple myeloma. J Hacettepe Univ Fac Nurs. 2018;5(3):260-267. https://orcid.org/0000-0002-7335-4032
  • 36.Lennan E, Roe H. Role of nurses in the assessment and management of chemotherapy-related side effects in cancer patients. Nurs Res Rev. 2014;4:103-115. doi:10.2147/nrr.s41845

Myeloma Comes as a Staple: A Case Report of the Roy Adaptation Model

Yıl 2023, , 263 - 271, 08.09.2023
https://doi.org/10.32708/uutfd.1273377

Öz

In individuals with multiple myeloma, symptom management includes specific problems such as infection, anemia, pain and coagulation disorders, especially symptoms related to bone disease and kidney dysfunction. As in other diseases, nursing care has an important place in the diagnosis and treatment process of the patient with myeloma. Nursing care models contribute to increasing the quality of care by providing a systematic and comprehensive treatment of the patient. The Roy Adaptation Model is one of them. In the Roy Adaptation model, there are four areas of adaptation: physiological, self-concept, role function and interdependence, and nurses care for their patients in line with these adaptation areas. In this case report, a patient who was diagnosed with lambda light chain, stage III B multiple myeloma according to Durie Salmon with radiological, laboratory, cytogenetic and clinical findings and who presented with low back pain and an outpatient chemotherapy treatment plan was prepared is discussed. This case report has been prepared to guide nurses working in the field of hematology and oncology about the care given to a patient with multiple myeloma in line with the Roy Adaptation Model, together with the nursing diagnoses of the North American Nursing Diagnosis Association.

Kaynakça

  • 1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020 : GLOBOCAN estimates of ıncidence and mortality worldwide for 36 cancers in 185 countries. 2021;0(0):1-41. doi:10.3322/caac.21660
  • 2. Public Health Institution. 2013 - 2018 National Cancer Control Plan, T.C. Ministry of Health. Page 0-94.
  • 3. Konstantinidis TI, Spinthouri M, Ramoutsaki A, Marnelou A, Kritsotakis G, Govina O. Assessment of unmet supportive care needs in haematological cancer survivors. Asian Pacific J Cancer Prev. 2019;20(5):1487-1495. doi:10.31557/APJCP.2019.20.5.1487
  • 4. Boland EG, Boland JW, Ezaydi Y, Greenfield DM, Ahmedzai SH, Snowden JA. Holistic needs assessment in advanced, intensively treated multiple myeloma patients. Support Care Cancer. 2014;22(10):2615-2620. doi:10.1007/s00520-014-2231-2
  • 5. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086-1107. doi:10.1002/ajh.26590
  • 6. World Health Organisation. Global multiple myeloma statistics. International Agency for Research on Cancer. Published 2020. Accessed February 23, 2022. https://gco.iarc.fr/today/data/factsheets/cancers/35-Multiple-myeloma-fact-sheet.pdf
  • 7. Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(94):1-10. doi:10.1038/s41408-020-00359-2
  • 8. Kleber M, Ntanasis-Stathopoulos I, Terpos E. BCMA in multiple myeloma a promising key to therapy. J Clin Med. 2021;10(18):1-17. doi:10.3390/jcm10184088
  • 9. Aghaee M, Ledzewicz U, Robbins M, Bezman N, Jay H, Moore H. European Journal of Pharmaceutical Sciences Determining optimal combination regimens for patients with multiple myeloma. Eur J Pharm Sci. 2023;187(June):106492. doi:10.1016/j.ejps.2023.106492
  • 10. Gallaher J, Larripa K, Renardy M, et al. Methods for determining key components in a mathematical model for tumor–immune dynamics in multiple myeloma. J Theor Biol. 2018;438(7):31-46.
  • 11.Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label,randomized trial. J Clin Oncol. 2011;29(8):986-993. doi:10.1200/JCO.2010.31.6844
  • 12.NCCN. NCCN Guidelines Version 4.2022 Multiple Myeloma.NCCN Clinical Practice Guidelines in Oncology (NCCNGuidelines® ). Published 2021. www.nccn.org/patients
  • 13.Zeng L, Huang H, Liu Y, et al. The core symptom in multiplemyeloma patients undergoing chemotherapy: a networkanalysis. Support Care Cancer. 2023;31(5):297. doi:10.1007/s00520-023-07759-7
  • 14.Nielsen LK, Larsen RF, Jarlbaek L, Möller S, Jespersen E. Health-related quality of life in patients with multiple myelomaparticipating in a multidisciplinary rehabilitation program. Ann Hematol. 2021;100(9):2311-2323. doi:10.1007/s00277-020-04356-0
  • 15.Ovayolu O, Ovayolu N, Aytac S, Serçe S, Sevinc A. Pain in cancer patients: pain assessment by patients and family caregivers and problems experienced by caregivers. Support Care Cancer. 2015;23(7):1857-1864. doi:10.1007/s00520-014-2540-5
  • 16.Bertolotti P, Colson K, Bilotti E, Curran K, Doss D, Faiman B.Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the International Myeloma Foundation’s Nurse Leadership Board. Clin J Oncol Nurs. 2008;12(30):9-12. doi:10.1188/08.CJON.S1.9-12.
  • 17.Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548. doi:10.1016/S1470-2045(14)70442-5
  • 18.Jones & Bartlett Learning L. The Roy Adaption Model: SisterCallista Roy. In: Nursing Theories: A Framework for Professional Practice. Jones-Bartlett Learning, LLC; 1991:127-142. http://samples.jbpub.com/9781449626013/72376_ch10_masters.pdf
  • 19.Maryati I, S S, Mamuroh L. the Application of “Roy Adaptation” theory model in women with early stage ofcervical cancer: a study case. J Matern Care Reprod Heal. 2018;1(2):386-397. doi:10.36780/jmcrh.v1i2.47
  • 20.Jennings KM. The Roy adaptation model: A theoretical framework for nurses providing care to individuals with anorexia nervosa. Adv Nurs Sci. 2017;40(4):370-383. doi:10.1097/ANS.0000000000000175
  • 21.Ursavaş FE, Karayurt Ö, İşeri Ö. Nursing approach based onRoy Adaptation Model in a patient undergoing breast conserving surgery for breast cancer. J Breast Heal. 2014;10:134-140.
  • 22.Akyol E, İbrahimoğlu Ö. Kalp Nakli Olan Hastanın Roy Adaptasyon Modeli’ne göre hemşirelik bakımı. J Cardiovasc Nurs. 2020;11(26):140-148. doi:10.5543/khd.2020.21043
  • 23.Roy C. Extending the roy adaptation model to meet changing global needs. Nurs Sci Q. 2011;24(4):345-351. doi:10.1177/0894318411419210
  • 24.Ramini SK, Brown R, Buckner EB. Embracing changes: adaptation by adolescents with cancer. Pediatr Nurs. 2008;34(1):72-79.
  • 25.Hannon-Engel SL. Knowledge Development: The RoyAdaptation Model and Bulimia nervosa. Nurs Sci Q. 2008;21(2):126-132. doi:10.1177/0894318408315015
  • 26.Yıldız E, Karagözoğlu Ş. Lenfoma tanısı alan yetişkin bireyin roy adaptasyon modeline göre hemşirelik bakımı. J Heal Sci. 2015;90(312):0-2.
  • 27.Menekli T, Çil Eyi S. Use of Roy Adaptation model in nursingcare of a case obesity. Florence Nightingale Hemşirelik Derg. 2017;25(3):237-246. doi:10.17672/fnjn.343263
  • 28.Baksi Şimşek A, Dicle A. Nursing model and care: evaluation with the Roy Adaptation Model of patients with primary brain tumor. Hemşirelikte Eğitim ve Araştırma Derg. 2015;12(3):224-232. doi:10.5222/head.2015.224
  • 29.Özkaraman A, Özer S, Balcı Alpaslan G. Romatoid artritli bir vakanın hemşirelik bakımında Roy Adaptasyon Modelininkullanımı. Gümüşhane Üniversitesi Sağlık Bilim Derg. 2012;1(3):138-152.https://dergipark.org.tr/tr/pub/gumussagbil/98959
  • 30.Wilkinson JM, Barcus L. Pearson Hemş􀧻rel􀧻k Tanıları El K􀧻tabı : NANDA-I Tanılar, NIC G􀧻r􀧻ş􀧻mler􀧻, NOC Çıktıları. 11th ed. (Kapucu S, Akyar I, Korkmaz F, eds.). Pelikan Yayınevi; 2018.
  • 31.Fawcett J. Contemporary nursing knowledge analysis and evoulation of nursing models and theories. 2th ed. Philadelphia: Fa Davis Company; 2005.
  • 32.Longacre ML, Weber-Raley L, Kent EE. Cancer caregiving while employed: caregiving roles, employment adjustments, employer assistance, and preferences for support. https://doi.org/10.1007/s13187-019-01674-4. J Cancer Educ. Published online 2019. doi:10.1007/s13187-019-01674-4
  • 33.Kiyancicek Z, Caydam DO. Spırıtual needs and practıces among famıly caregıvers of patıents wıth cancer. Acta Paul Enferm. 2017;30(6):628-634.
  • 34.Huang MF, Huang WH, Su YC, et al. Coping Strategy and Caregiver Burden among Caregivers of Patients with Dementia. Am J Alzheimers Dis Other Demen. 2015;30(7):694-698. doi:10.1177/1533317513494446
  • 35.Ovayolu Ö, Ovayolu N. Multipl miyelom tanısı alan geriatrik hastalarda ağrı ve yönetimi pain and ıts management in geriatric patients diagnosed with multiple myeloma. J Hacettepe Univ Fac Nurs. 2018;5(3):260-267. https://orcid.org/0000-0002-7335-4032
  • 36.Lennan E, Roe H. Role of nurses in the assessment and management of chemotherapy-related side effects in cancer patients. Nurs Res Rev. 2014;4:103-115. doi:10.2147/nrr.s41845
Toplam 36 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Hematoloji, Hemşirelik
Bölüm Olgu Bildirimi Makaleler
Yazarlar

Yasemin Karacan 0000-0001-8616-4935

Hicran Yıldız 0000-0003-4241-5231

Rıdvan Ali 0000-0001-6486-3399

Yayımlanma Tarihi 8 Eylül 2023
Kabul Tarihi 21 Temmuz 2023
Yayımlandığı Sayı Yıl 2023

Kaynak Göster

APA Karacan, Y., Yıldız, H., & Ali, R. (2023). Miyelom Zimba Gibi Gelir: Roy Adaptasyon Modeli Bir Olgu Sunumu. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 49(2), 263-271. https://doi.org/10.32708/uutfd.1273377
AMA Karacan Y, Yıldız H, Ali R. Miyelom Zimba Gibi Gelir: Roy Adaptasyon Modeli Bir Olgu Sunumu. Uludağ Tıp Derg. Eylül 2023;49(2):263-271. doi:10.32708/uutfd.1273377
Chicago Karacan, Yasemin, Hicran Yıldız, ve Rıdvan Ali. “Miyelom Zimba Gibi Gelir: Roy Adaptasyon Modeli Bir Olgu Sunumu”. Uludağ Üniversitesi Tıp Fakültesi Dergisi 49, sy. 2 (Eylül 2023): 263-71. https://doi.org/10.32708/uutfd.1273377.
EndNote Karacan Y, Yıldız H, Ali R (01 Eylül 2023) Miyelom Zimba Gibi Gelir: Roy Adaptasyon Modeli Bir Olgu Sunumu. Uludağ Üniversitesi Tıp Fakültesi Dergisi 49 2 263–271.
IEEE Y. Karacan, H. Yıldız, ve R. Ali, “Miyelom Zimba Gibi Gelir: Roy Adaptasyon Modeli Bir Olgu Sunumu”, Uludağ Tıp Derg, c. 49, sy. 2, ss. 263–271, 2023, doi: 10.32708/uutfd.1273377.
ISNAD Karacan, Yasemin vd. “Miyelom Zimba Gibi Gelir: Roy Adaptasyon Modeli Bir Olgu Sunumu”. Uludağ Üniversitesi Tıp Fakültesi Dergisi 49/2 (Eylül 2023), 263-271. https://doi.org/10.32708/uutfd.1273377.
JAMA Karacan Y, Yıldız H, Ali R. Miyelom Zimba Gibi Gelir: Roy Adaptasyon Modeli Bir Olgu Sunumu. Uludağ Tıp Derg. 2023;49:263–271.
MLA Karacan, Yasemin vd. “Miyelom Zimba Gibi Gelir: Roy Adaptasyon Modeli Bir Olgu Sunumu”. Uludağ Üniversitesi Tıp Fakültesi Dergisi, c. 49, sy. 2, 2023, ss. 263-71, doi:10.32708/uutfd.1273377.
Vancouver Karacan Y, Yıldız H, Ali R. Miyelom Zimba Gibi Gelir: Roy Adaptasyon Modeli Bir Olgu Sunumu. Uludağ Tıp Derg. 2023;49(2):263-71.

ISSN: 1300-414X, e-ISSN: 2645-9027

Uludağ Üniversitesi Tıp Fakültesi Dergisi "Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License" ile lisanslanmaktadır.


Creative Commons License
Journal of Uludag University Medical Faculty is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

2023